Lilly Reports Solid First-Quart...(marily to increased demand and the favor...)

Forteo

First-quarter sales of Forteo were $185.0 million, a 21 percent increase compared with the first quarter of 2007. U.S. sales of Forteo increased 10 percent, to $118.3 million, driven primarily by increased volume caused by variations in wholesaler buying patterns, as well as by higher prices. Sales outside the U.S. grew 45 percent, to $66.7 million, due to higher demand and the favorable impact of foreign exchange rates.

Strattera

During the first quarter of 2008, Strattera generated $148.0 million of sales, an increase of 6 percent compared with the first quarter of 2007. U.S. sales decreased 2 percent, to $115.5 million, due to a decline in demand, offset in part by higher prices. Sales outside the U.S. increased 47 percent, to $32.6 million, due primarily to higher demand and the favorable impact of foreign exchange rates.

Other Diabetes Care Products

As previously disclosed, Lilly's U.S. marketing rights with respect to Actos(R) expired in September 2006; however, Lilly will continue to receive royalties from Takeda Pharmaceuticals North America at a declining rate through September 2009. Lilly continues to market the product in many countries outside the U.S. In the first quarter of 2008, Actos generated $84.1 million of revenue for Lilly, the majority of which was outside the U.S. Actos revenue decreased 2 percent versus the first quarter of 2007.

Worldwide sales of Byetta were $169.0 million in the first quarter of 2008, a 15 percent increase compared with the first quarter of 2007. U.S. Byetta sales grew 8 percent, to $158.5 million. Byetta sales outside the U.S. were $10.5 million. Lilly reports as revenue its 50 percent share of Byetta's gross margin in the U.S., 100 percent of Byetta sales outside the U.S., and its sales of Byetta pen delivery devices to its partner, Amylin Pharmaceuticals
'/>"/>